menu
    • menu
    [{"orgOrder":0,"company":"Genascence","sponsor":"Pacira BioSciences","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell and Gene therapy","year":"2022","type":"Series A Financing","leadProduct":"sc-rAAV2.5IL-1Ra","moa":"","graph1":"Musculoskeletal","graph2":"Phase II","graph3":"Genascence","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Musculoskeletal","amount2New":0.01,"dosageForm":"Inhalation","sponsorNew":"Genascence \/ Pacira BioSciences","highestDevelopmentStatusID":"8","companyTruncated":"Genascence \/ Pacira BioSciences"},{"orgOrder":0,"company":"Genascence","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"sc-rAAV2.5IL-1Ra","moa":"","graph1":"Musculoskeletal","graph2":"Phase I","graph3":"Genascence","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Musculoskeletal","amount2New":0,"dosageForm":"Injection","sponsorNew":"Genascence \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Genascence \/ Not Applicable"},{"orgOrder":0,"company":"Genascence","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Musculoskeletal","country":"U.S.A","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"sc-rAAV2.5IL-1Ra","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Genascence","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Genascence \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Genascence \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Genascence

    Menu

    Genascence

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Genascence

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Genascence

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : sc-rAAV2.5IL-1Ra

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Genascence Granted FDA Fast Track Designation for GNSC-001 in OA

                            Details : GNSC-001 (sc-rAAV2.5IL-1Ra) is a recombinant adeno-associated viral vector expressing candidate that blocks IL-1 signaling, for the treatment of Knee Osteoarthritis.

                            Brand Name : GNSC-001

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            November 12, 2024

                            Lead Product(s) : sc-rAAV2.5IL-1Ra

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Genascence

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Genascence

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : sc-rAAV2.5IL-1Ra

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Genascence Initiates Phase 1b Trial Of GNSC-001 Gene Therapy

                            Details : GNSC-001 (sc-rAAV2.5IL-1Ra) is a genetic medicine using a viral vector to express IL-1Ra, blocking IL-1 signaling, and is in phase 1 development for Knee Osteoarthritis.

                            Brand Name : GNSC-001

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            January 03, 2024

                            Lead Product(s) : sc-rAAV2.5IL-1Ra

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Genascence

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Genascence

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : sc-rAAV2.5IL-1Ra

                            Therapeutic Area : Musculoskeletal

                            Study Phase : Phase II

                            Sponsor : Pacira BioSciences

                            Deal Size : $10.5 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Genascence Announces First Close in Series A Financing led by Pacira BioSciences and Expands Board of Director...

                            Details : GNSC-001 is an adeno-associated vector (AAV) carrying a coding sequence for interleukin-1 receptor antagonist (IL-1Ra), a potent inhibitor of interleukin-1 (IL-1) signaling.

                            Brand Name : GNSC-001

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            May 10, 2022

                            Lead Product(s) : sc-rAAV2.5IL-1Ra

                            Therapeutic Area : Musculoskeletal

                            Highest Development Status : Phase II

                            Sponsor : Pacira BioSciences

                            Deal Size : $10.5 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth